ASC40

ASC40 (TVB-2640) is a small-molecule drug developed by Ascletis Pharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: ASC40 tablets administered orally once daily. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05118776 (Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM), in glioma & glioblastoma. The largest, NCT05118776, plans to enrol 136 participants (actual) with primary completion expected 2025-06. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.